Results 171 to 180 of about 178,566 (304)

CDR report

Critical Design Review (CDR) report with documentation of finalized design and set of construction documents ready to initiate manufacturing and procurement of hardware and ...
openaire   +1 more source

Clinical outcomes of the PAUL® glaucoma implant for secondary glaucoma

Acta Ophthalmologica, EarlyView.
Abstract Purpose Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option.
Carolin Deubel, Benjamin Aretz, Wolfgang Walz, Michael Petrak, Frank G. Holz, Raffael Liegl, Karl Mercieca, Constance Liegl   +7 more
wiley   +1 more source

Recommendations for CDR

Provide recommendations regarding Certificates for Carbon Dioxide Removals.
openaire   +1 more source

Structural retinal changes and visual field loss across timing of damage in children with cerebral visual impairment

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate structural changes in the retina and optic nerve head (ONH) of children with cerebral visual impairment (CVI) across different timing of damage (TOD), and to relate these structural changes to visual field (VF) loss severity and pattern.
Jannet Philip, Frouke Nienke Boonstra, Nomdo M. Jansonius   +2 more
wiley   +1 more source

DiAbot: A Conversational AI System Coupling Large Language Models with an Interpretable Decision Tree for CDR-Style Dementia Screening. [PDF]

Bioengineering (Basel)
Alshamlan H.
europepmc   +1 more source

Incidence of Childhood Dilated Cardiomyopathy in Sweden From 1991 to 2019: A National Population‐Based Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim To study the incidence, survival, and mortality of dilated cardiomyopathy (DCM) in children in Sweden, 1991–2019. Methods Hospital records of 0–18‐year‐olds diagnosed with DCM over a 29‐year period were reviewed. The annual sex‐specific incidence rates of DCM were calculated as new disease cases, divided by the average Swedish same‐sex ...
Shalan Fadl, Stefan Särnblad, Tahir Taj, Håkan Wåhlander, Eva Fernlund, Jan Sunnegårdh   +5 more
wiley   +1 more source

Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations. [PDF]

Alzheimers Dement
Simmons A, Boeve B, Ber IL, Borroni B, Mummery C, Rohrer JD, Zamboni G, Onur OA, Rowe JB, Boxer AL, Schwabe T, Kahn OI, Huang JY, Long H, Gupta R, Zhong J, Li C, Guizzetti L, Carter LP, Nguyen T, Chow TW, Budda B, Park L, Jackson S, Paul R, Ward M, Romano G, Kenkare-Mitra S, Rosenthal A, Salvadore G, Mayorga AJ.   +30 more
europepmc   +1 more source

Amygdala vulnerability in Pick disease with discrete frontotemporal dementia syndromes

Brain Pathology, EarlyView.
Clinicopathological characterization of the amygdala in FTLD‐tau. Amygdala vulnerability in FTLD‐tauopathies is defined by elevated neuroinflammation and tau in 3R versus 4R subtypes, and greater neuroinflammation in bvFTD versus PPA. In Pick disease, bvFTD and PPA converge neuropsychiatrically over time, and intracellular tau correlates with increased
Rachel Keszycki, Allegra Kawles, Grace Minogue, Antonia Zouridakis, Alyssa Macomber, Caroline Nelson, Qinwen Mao, Rudolph J. Castellani, Pouya Jamshidi, Nathan Gill, Sandra Weintraub, M.‐Marsel Mesulam, Changiz Geula, Tamar Gefen   +13 more
wiley   +1 more source

Real-world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China. [PDF]

Alzheimers Dement
Tang L, Chen X, Zhang L, Fan L, Chen N, Li C, Cai Z, Chen G, Chen H, Ye M, Zheng H, Li Q, Ke Z, Hu Z, Cao M, Yang D, Xu S, Xie C, Li X, Xu X, Yu M, Lian X, Hu H, Li H, Cai X, Chen H, Xu W, Cui G, Zhao Y, Dong J, Zhang L, Zhu X, Zhao H, Xu Y.   +33 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source